The corticostriatal pathway in Huntington's disease

Progress in Neurobiology

Volumn 81, Issue 5-6, 2007, Pages 253-271

  Cepeda, Carlos ^a   Wu, Nanping ^a   André, Véronique M ^a   Cummings, Damian M ^a   Levine, Michael S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cortex; Electrophysiology; Glutamate; Mouse models; Pathway; Striatum

Indexed keywords

4 AMINOBUTYRIC ACID; BENZODIAZEPINE DERIVATIVE; BRAIN DERIVED NEUROTROPHIC FACTOR; ENKEPHALIN; GLUTAMATE RECEPTOR; GLUTAMIC ACID; LEVODOPA; RILUZOLE;

CELL LOSS; CELL SUBPOPULATION; CLINICAL TRIAL; CORPUS STRIATUM; ELECTROPHYSIOLOGY; EVOKED RESPONSE; HUMAN; HUNTINGTON CHOREA; MORPHOLOGY; NERVE CELL; NERVE CELL PLASTICITY; NONHUMAN; PHENOTYPE; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

ANIMALS; CEREBRAL CORTEX; CORPUS STRIATUM; HUMANS; HUNTINGTON DISEASE; NEURAL PATHWAYS;

EID: 34047180648     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2006.11.001     Document Type: Review

References (248)

1. Aizman O., Brismar H., Uhlen P., Zettergren E., Levey A.I., Forssberg H., Greengard P., and Aperia A. Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons. Nat. Neurosci. 3 (2000) 226-230
2. Albanese A., Cassetta E., Carretta D., Bentivoglio A.R., and Tonali P. Acute challenge with apomorphine in Huntington's disease: a double-blind study. Clin. Neuropharmacol. 18 (1995) 427-434
3. Alberch J., Perez-Navarro E., and Canals J.M. Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease. Brain Res. Bull. 57 (2002) 817-822
4. Alberch J., Perez-Navarro E., and Canals J.M. Neurotrophic factors in Huntington's disease. Prog. Brain Res. 146 (2004) 195-229
5. Albin R.L., Young A.B., and Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12 (1989) 366-375
6. Ali N.J., and Levine M.S. Changes in expression of N-methyl-d-aspartate receptor subunits occur early in the R6/2 mouse model of Huntington's disease. Dev. Neurosci. 28 (2006) 230-238
7. André V.M., Cepeda C., Venegas A., Gomez Y., and Levine M.S. Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease. J. Neurophysiol. 95 (2006) 2108-2119
8. Ariano M.A., Aronin N., Difiglia M., Tagle D.A., Sibley D.R., Leavitt B.R., Hayden M.R., and Levine M.S. Striatal neurochemical changes in transgenic models of Huntington's disease. J. Neurosci. Res. 68 (2002) 716-729
9. Ariano M.A., Cepeda C., Calvert C.R., Flores-Hernandez J., Hernandez-Echeagaray E., Klapstein G.J., Chandler S.H., Aronin N., DiFiglia M., and Levine M.S. Striatal potassium channel dysfunction in Huntington's disease transgenic mice. J. Neurophysiol. 93 (2005) 2565-2574
10. Ariano M.A., Wagle N., and Grissell A.E. Neuronal vulnerability in mouse models of Huntington's disease: membrane channel protein changes. J. Neurosci. Res. 80 (2005) 634-645
11. Ayalon L., Doron R., Weiner I., and Joel D. Amelioration of behavioral deficits in a rat model of Huntington's disease by an excitotoxic lesion to the globus pallidus. Exp. Neurol. 186 (2004) 46-58
12. Bamford N.S., Zhang H., Schmitz Y., Wu N.P., Cepeda C., Levine M.S., Schmauss C., Zakharenko S.S., Zablow L., and Sulzer D. Heterosynaptic dopamine neurotransmission selects sets of corticostriatal terminals. Neuron 42 (2004) 653-663
13. Baquet Z.C., Gorski J.A., and Jones K.R. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J. Neurosci. 24 (2004) 4250-4258
14. Bates G.P., and Murphy K.P. Mouse models of Huntington's disease. In: Bates G.P., Harper P.S., and Jones A.L. (Eds). Huntington's Disease (2002), Oxford University Press, Oxford, UK 387-426
15. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J., and Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321 (1986) 168-171
16. Behrens P.F., Franz P., Woodman B., Lindenberg K.S., and Landwehrmeyer G.B. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain 125 (2002) 1908-1922
17. Bennett B.D., and Bolam J.P. Synaptic input and output of parvalbumin-immunoreactive neurons in the neostriatum of the rat. Neuroscience 62 (1994) 707-719
18. Bennett B.D., and Wilson C.J. Spontaneous activity of neostriatal cholinergic interneurons in vitro. J. Neurosci. 19 (1999) 5586-5596
19. Berretta S., Parthasarathy H.B., and Graybiel A.M. Local release of GABAergic inhibition in the motor cortex induces immediate-early gene expression in indirect pathway neurons of the striatum. J. Neurosci. 17 (1997) 4752-4763
20. Bibb J.A., Yan Z., Svenningsson P., Snyder G.L., Pieribone V.A., Horiuchi A., Nairn A.C., Messer A., and Greengard P. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 6809-6814
21. Bizière K., and Coyle J.T. Effects of cortical ablation on the neurotoxicity and receptor binding of kainic acid in striatum. J. Neurosci. Res. 4 (1979) 383-398
22. Blum D., Gall D., Galas M.C., d'Alcantara P., Bantubungi K., and Schiffmann S.N. The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. J. Neurosci. 22 (2002) 9122-9133
23. Blum D., Hourez R., Galas M.C., Popoli P., and Schiffmann S.N. Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. Lancet Neurol. 2 (2003) 366-374
24. Blum D., Galas M.C., Pintor A., Brouillet E., Ledent C., Muller C.E., Bantubungi K., Galluzzo M., Gall D., Cuvelier L., Rolland A.S., Popoli P., and Schiffmann S.N. A dual role of adenosine A2A receptors in 3 nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists. J. Neurosci. 23 (2003) 5361-5369
25. Borrell-Pages M., Canals J.M., Cordelieres F.P., Parker J.A., Pineda J.R., Grange G., Bryson E.A., Guillermier M., Hirsch E., Hantraye P., Cheetham M.E., Neri C., Alberch J., Brouillet E., Saudou F., and Humbert S. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J. Clin. Invest. 116 (2006) 1410-1424
26. Bozzi Y., and Borrelli E. Dopamine in neurotoxicity and neuroprotection: what do D2 receptors have to do with it?. Trends Neurosci. 29 (2006) 167-174
27. Brouillet E., Condé F., Beal M.F., and Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 59 (1999) 427-468
28. A receptor surface expression. Eur. J. Neurosci. 13 (2001) 1320-1328
29. Calabresi P., Mercuri N.B., De Murtas M., and Bernardi G. Endogenous GABA mediates presynaptic inhibition of spontaneous and evoked excitatory synaptic potentials in the rat neostriatum. Neurosci. Lett. 118 (1990) 99-102
30. Calabresi P., Centonze D., Pisani A., Sancesario G., Gubellini P., Marfia G.A., and Bernardi G. Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: implications for ischemia and Huntington's disease. Ann. Neurol. 43 (1998) 586-597
31. Calabresi P., Centonze D., and Bernardi G. Cellular factors controlling neuronal vulnerability in the brain: a lesson from the striatum. Neurology 55 (2000) 1249-1255
32. Calabresi P., Gubellini P., Picconi B., Centonze D., Pisani A., Bonsi P., Greengard P., Hipskind R.A., Borrelli E., and Bernardi G. Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. J. Neurosci. 21 (2001) 5110-5120
33. Carlsson A., Falck B., and Hillarp N.A. Cellular localization of brain monoamines. Acta Physiol. Scand. 56 Suppl. 196 (1962) 1-28
34. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., and Morton A.J. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 19 (1999) 3248-3257
35. Carter R.J., Hunt M.J., and Morton A.J. Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene. Mov. Disord. 15 (2000) 925-937
36. Cattaneo E., Rigamonti D., Goffredo D., Zuccato C., Squitieri F., and Sipione S. Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci. 24 (2001) 182-188
37. Cattaneo E., Zuccato C., and Tartari M. Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 6 (2005) 919-930
38. Centonze D., Calabresi P., Pisani A., Marinelli S., Marfia G.A., and Bernardi G. Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons. Neuropharmacology 37 (1998) 1063-1070
39. Centonze D., Gubellini P., Picconi B., Saulle E., Tolu M., Bonsi P., Giacomini P., and Calabresi P. An abnormal striatal synaptic plasticity may account for the selective neuronal vulnerability in Huntington's disease. Neurol. Sci. 22 (2001) 61-62
40. Centonze D., Rossi S., Prosperetti C., Tscherter A., Bernardi G., Maccarrone M., and Calabresi P. Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice. Biol. Psychiatry 57 (2005) 1583-1589
41. Cepeda C., and Levine M.S. Dopamine and N-methyl-d-aspartate receptor interactions in the neostriatum. Dev. Neurosci. 20 (1998) 1-18
42. Cepeda C., and Levine M.S. Where do you think you are going? The NMDA-D1 receptor trap. Sci. STKE 333 (2006) pe20
43. Cepeda C., Ariano M.A., Calvert C.R., Flores-Hernandez J., Chandler S.H., Leavitt B.R., Hayden M.R., and Levine M.S. NMDA receptor function in mouse models of Huntington disease. J. Neurosci. Res. 66 (2001) 525-539
44. Cepeda C., Hurst R.S., Altemus K.L., Flores-Hernandez J., Calvert C.R., Jokel E.S., Grandy D.K., Low M.J., Rubinstein M., Ariano M.A., and Levine M.S. Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice. J. Neurophysiol. 85 (2001) 659-670
45. Cepeda C., Itri J.N., Flores-Hernández J., Hurst R.S., Calvert C.R., and Levine M.S. Differential sensitivity of medium- and large-sized striatal neurons to NMDA but not kainate receptor activation in the rat. Eur. J. Neurosci. 14 (2001) 1577-1589
46. Cepeda C., Hurst R.S., Calvert C.R., Hernandez-Echeagaray E., Nguyen O.K., Jocoy E., Christian L.J., Ariano M.A., and Levine M.S. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J. Neurosci. 23 (2003) 961-969
47. Cepeda C., Starling A.J., Wu N., Nguyen O.K., Uzgil B., Soda T., Andre V.M., Ariano M.A., and Levine M.S. Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF. J. Neurosci. Res. 78 (2004) 855-867
48. Cepeda C., Starling A.J., Wu N., Soda T., Lobo M.K., Yang X.W., and Levine M.S. Defining electrophysiological properties of subpopulations of striatal neurons using genetic expression of enhanced green fluorescent protein. Soc. Neurosci. Abst. 30 (2004) 307.4
49. Cepeda, C., Hickey, M.A., Kleiman-Weiner, M., Yamazaki, I., Wu, N., Beroukhim, B., Watson, J.B., Levine, M.S., 2006. Effects of voluntary exercise on the Huntington's disease phenotype in the R6/2 mouse model. Soc. Neurosci. Abstr. (Program No. 758.5).
50. Cha J.H., Kosinski C.M., Kerner J.A., Alsdorf S.A., Mangiarini L., Davies S.W., Penney J.B., Bates G.P., and Young A.B. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 6480-6485
51. B receptors in the basal ganglia in monkeys. Neuroscience 95 (2000) 127-140
52. Charpier S., and Deniau J.M. In vivo activity-dependent plasticity at cortico-striatal connections: evidence for physiological long-term potentiation. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 7036-7040
53. 2+ channel activity is upregulated in cortical neurons in R6/2 Huntington's disease (HD) transgenic mice. Soc. Neurosci. Abstr. (Program No. 92.13).
54. Chou S.Y., Lee Y.C., Chen H.M., Chiang M.C., Lai H.L., Chang H.H., Wu Y.C., Sun C.N., Chien C.L., Lin Y.S., Wang S.C., Tung Y.Y., Chang C., and Chern Y. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J. Neurochem. 93 (2005) 310-320
55. Cicchetti F., Gould P.V., and Parent A. Sparing of striatal neurons coexpressing calretinin and substance P (NK1) receptor in Huntington's disease. Brain Res. 730 (1996) 232-237
56. Corsini G.U., Onali P., Masala C., Cianchetti C., Mangoni A., and Gessa G. Apomorphine hydrochloride-induced improvement in Huntington's chorea: stimulation of dopamine receptor. Arch. Neurol. 35 (1978) 27-30
57. Cotman C.W., and Berchtold N.C. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci. 25 (2002) 295-301
58. Cudkowicz M., and Kowall N.W. Degeneration of pyramidal projection neurons in Huntington's disease cortex. Ann. Neurol. 27 (1990) 200-204
59. Cummings D.M., Milnerwood A.J., Dallérac G.M., Waights V., Brown J.Y., Vatsavayai S.C., Hirst M.C., and Murphy K.P.S.J. Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. Hum. Mol. Genet. 15 (2006) 2856-2868
60. Cummings, D.M., Uzgil, B.O., Marcolino, B.F., André, V.M., Cepeda, C., Levine, M.S., 2006b. Reduced GABAergic inhibition in the cortex of the R6/2 mouse model of Huntington's disease. Soc. Neurosci. Abstr. (Program No. 472.2).
61. Dalbem A., Silveira C.V., Pedroso M.F., Breda R.V., Werne Baes C.V., Bartmann A.P., and da Costa J.C. Altered distribution of striatal activity-dependent synaptic plasticity in the 3-nitropropionic acid model of Huntington's disease. Brain Res. 1047 (2005) 148-158
62. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., and Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90 (1997) 537-548
63. de la Monte S.M., Vonsattel J.P., and Richardson Jr. E.P. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J. Neuropathol. Exp. Neurol. 47 (1988) 516-525
64. Deng Y.P., Albin R.L., Penney J.B., Young A.B., Anderson K.D., and Reiner A. Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study. J. Chem. Neuroanat. 27 (2004) 143-164
65. Diaz-Hernandez M., Torres-Peraza J., Salvatori-Abarca A., Moran M.A., Gomez-Ramos P., Alberch J., and Lucas J.J. Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease. J. Neurosci. 25 (2005) 9773-9781
66. DiFiglia M. Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci. 13 (1990) 286-289
67. DiFiglia M., Sapp E., Chase K., Schwarz C., Meloni A., Young C., Martin E., Vonsattel J.P., Carraway R., Reeves S.A., Boyce F.M., and Aronin N. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 14 (1995) 1075-1081
68. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., and Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277 (1997) 1990-1993
69. Dos Santos Villar F., and Walsh J.P. Modulation of long-term synaptic plasticity at excitatory striatal synapses. Neuroscience 90 (1999) 1031-1041
70. Duan W., Guo Z., Jiang H., Ware M., Li X.J., and Mattson M.P. Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 2911-2916
71. Ferrante R.J., Gutekunst C.A., Persichetti F., McNeil S.M., Kowall N.W., Gusella J.F., MacDonald M.E., Beal M.F., and Hersch S.M. Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. J. Neurosci. 17 (1997) 3052-3063
72. Fino E., Glowinski J., and Venance L. Bidirectional activity-dependent plasticity at corticostriatal synapses. J. Neurosci. 25 (2005) 11279-11287
73. Flores-Hernandez J., Galarraga E., and Bargas J. Dopamine selects glutamatergic inputs to neostriatal neurons. Synapse 25 (1997) 185-195
74. Fonnum F., Storm-Mathisen J., and Divac I. Biochemical evidence for glutamate as a neurotransmitter in corticostriatal and corticothalamic fibres in rat brain. Neuroscience 6 (1981) 863-873
75. Frim D.M., Simpson J., Uhler T.A., Short M.P., Bossi S.R., Breakefield X.O., and Isacson O. Striatal degeneration induced by mitochondrial blockade is prevented by biologically delivered NGF. J. Neurosci. Res. 35 (1993) 452-458
76. Fusco F.R., Chen Q., Lamoreaux W.J., Figueredo-Cardenas G., Jiao Y., Coffman J.A., Surmeier D.J., Honig M.G., Carlock L.R., and Reiner A. Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease. J. Neurosci. 19 (1999) 1189-1202
77. Fusco F.R., Martorana A., De March Z., Viscomi M.T., Sancesario G., and Bernardi G. Huntingtin distribution among striatal output neurons of normal rat brain. Neurosci. Lett. 339 (2003) 53-56
78. Gardoni F., Bellone C., Viviani B., Marinovich M., Meli E., Pellegrini-Giampietro D.E., Cattabeni F., and Di Luca M. Lack of PSD-95 drives hippocampal neuronal cell death through activation of an alpha CaMKII transduction pathway. Eur. J. Neurosci. 16 (2002) 777-786
79. Gauthier L.R., Charrin B.C., Borrell-Pages M., Dompierre J.P., Rangone H., Cordelieres F.P., De Mey J., MacDonald M.E., Lessmann V., Humbert S., and Saudou F. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118 (2004) 127-138
80. Gencik M., Hammans C., Strehl H., Wagner N., and Epplen J.T. Chorea Huntington: a rare case with childhood onset. Neuropediatrics 33 (2002) 90-92
81. Gerdeman G., and Lovinger D.M. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J. Neurophysiol. 85 (2001) 468-471
82. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci. 15 (1992) 133-139
83. Gibson H.E., Reim K., Brose N., Morton A.J., and Jones S. A similar impairment in CA3 mossy fibre LTP in the R6/2 mouse model of Huntington's disease and in the complexin II knockout mouse. Eur. J. Neurosci. 22 (2005) 1701-1712
84. Gines S., Bosch M., Marco S., Gavalda N., Diaz-Hernandez M., Lucas J.J., Canals J.M., and Alberch J. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain. Eur. J. Neurosci. 23 (2006) 649-658
85. Gong S., Zheng C., Doughty M.L., Losos K., Didkovsky N., Schambra U.B., Nowak N.J., Joyner A., Leblanc G., Hatten M.E., and Heintz N. A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425 (2003) 917-925
86. Gottmann K., Mehrle A., Gisselmann G., and Hatt H. Presynaptic control of subunit composition of NMDA receptors mediating synaptic plasticity. J. Neurosci. 17 (1997) 2766-2774
87. Graveland G.A., Williams R.S., and DiFiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 227 (1985) 770-773
88. Gu X., Li C., Wei W., Lo V., Gong S., Li S.H., Iwasato T., Itohara S., Li X.J., Mody I., Heintz N., and Yang X.W. Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 46 (2005) 433-444
89. Guidetti P., Charles V., Chen E.Y., Reddy P.H., Kordower J.H., Whetsell Jr. W.O., Schwarcz R., and Tagle D.A. Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. Exp. Neurol. 169 (2001) 340-350
90. Gutekunst C.A., Li S.H., Yi H., Mulroy J.S., Kuemmerle S., Jones R., Rye D., Ferrante R.J., Hersch S.M., and Li X.J. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 19 (1999) 2522-2534
91. Halliday G.M., McRitchie D.A., Macdonald V., Double K.L., Trent R.J., and McCusker E. Regional specificity of brain atrophy in Huntington's disease. Exp. Neurol. 154 (1998) 663-672
92. Halpain S., Hipolito A., and Saffer L. Regulation of F-actin stability in dendritic spines by glutamate receptors and calcineurin. J. Neurosci. 18 (1998) 9835-9844
93. A receptor agonists and antagonists in a genetic animal model of paroxysmal dystonia. Eur. J. Pharmacol. 443 (2002) 59-70
94. Hansson O., Petersén A., Leist M., Nicotera P., Castilho R.F., and Brundin P. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 8727-8732
95. Hardingham G.E., Fukunaga Y., and Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 5 (2002) 405-414
96. Harper P.S. Huntington's Disease. 2nd ed. (1996), W.B. Saunders, London
97. Hedreen J.C., Peyser C.E., Folstein S.E., and Ross C.A. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci. Lett. 133 (1991) 257-261
98. Hickey M.A., and Morton A.J. Mice transgenic for the Huntington's disease mutation are resistant to chronic 3-nitropropionic acid-induced striatal toxicity. J. Neurochem. 75 (2000) 2163-2171
99. Hickey M.A., and Chesselet M.F. The use of transgenic and knock-in mice to study Huntington's disease. Cytogenet. Genome Res. 100 (2003) 276-286
100. Hickey M.A., Reynolds G.P., and Morton A.J. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. J. Neurochem. 81 (2002) 46-59
101. Hickey M.A., Gallant K., Gross G.G., Levine M.S., and Chesselet M.F. Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol. Dis. 20 (2005) 1-11
102. Higgins D.S., Hoyt K.R., Baic C., Vensel J., and Sulka M. Metabolic and glutamatergic disturbances in the Huntington's disease transgenic mouse. Ann. N.Y. Acad. Sci. 893 (1999) 298-300
103. Hockly E., Cordery P.M., Woodman B., Mahal A., van Dellen A., Blakemore C., Lewis C.M., Hannan A.J., and Bates G.P. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann. Neurol. 51 (2002) 235-242
104. Hodgson J.G., Agopyan N., Gutekunst C.A., Leavitt B.R., LePiane F., Singaraja R., Smith D.J., Bissada N., McCutcheon K., Nasir J., Jamot L., Li X.J., Stevens M.E., Rosemond E., Roder J.C., Phillips A.G., Rubin E.M., Hersch S.M., and Hayden M.R. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23 (1999) 181-192
105. Hsu K.S., Huang C.C., Yang C.H., and Gean P.W. Presynaptic D2 dopaminergic receptors mediate inhibition of excitatory synaptic transmission in rat neostriatum. Brain Res. 690 (1995) 264-268
106. Huang C.C., Lo S.W., and Hsu K.S. Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J. Physiol. 532 (2001) 731-748
107. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
108. Huntington Study Group. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology 61 (2003) 1551-1556
109. Jones E. The Thalamus (1987), Plenum Press, New York
110. Joshi, P.R., Gomez, Y., Levine, M.S., 2006. Altered striatal AMPA receptor function in the R6/2 mouse model of Huntington's disease. Soc. Neurosci. Abstr. (Program No. 472.4).
111. Kartzinel R., Hunt R.D., and Calne D.B. Bromocriptine in Huntington chorea. Arch. Neurol. 33 (1976) 517-518
112. Kawaguchi Y., Wilson C.J., Augood S.J., and Emson P.C. Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci. 18 (1995) 527-535
113. Kemp J.M., and Powell T.P. The termination of fibres from the cerebral cortex and thalamus upon dendritic spines in the caudate nucleus: a study with the Golgi method. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 262 (1971) 429-439
114. Klapstein G.J., and Levine M.S. Age-dependent biphasic changes in ischemic sensitivity in the striatum of Huntington's disease R6/2 transgenic mice. J. Neurophysiol. 93 (2005) 758-765
115. Klapstein G.J., Fisher R.S., Zanjani H., Cepeda C., Jokel E.S., Chesselet M.-F., and Levine M.S. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J. Neurophysiol. 86 (2001) 2667-2677
116. Kubova H., and Mares P. Effects of alprazolam on a model of human absences-rhythmic metrazol activity in rats. Physiol. Res. 42 (1993) 361-364
117. Kullmann D.M., and Asztely F. Extrasynaptic glutamate spillover in the hippocampus: evidence and implications. Trends Neurosci. 21 (1998) 8-14
118. B receptors at glutamatergic synapses in the rat striatum. Neuroscience 136 (2005) 1083-1095
119. Laforet G.A., Sapp E., Chase K., McIntyre C., Boyce F.M., Campbell M., Cadigan B.A., Warzecki L., Tagle D.A., Reddy P.H., Cepeda C., Calvert C.R., Jokel E.S., Klapstein G.J., Ariano M.A., Levine M.S., DiFiglia M., and Aronin N. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J. Neurosci. 21 (2001) 9112-9123
120. Landwehrmeyer G.B., McNeil S.M., Dure IV L.S., Ge P., Aizawa H., Huang Q., Ambrose C.M., Duyao M.P., Bird E.D., Bonilla E., de Young M., Avila-Gonzales A.J., Wexler N.S., DiFiglia M., Gusella J.F., MacDonald M.E., Penney J.B., Young A.B., and Vonsattel J.P. Huntington's disease gene: regional and cellular expression in brain of normal and affected individuals. Ann. Neurol. 37 (1995) 218-230
121. Landwehrmeyer G.B., Standaert D.G., Testa C.M., Penny Jr. J.B., and Young A.B. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J. Neurosci. 15 (1995) 5297-5307
122. Lapper S.R., and Bolam J.P. Input from the frontal cortex and the parafascicular nucleus to cholinergic interneurons in the dorsal striatum of the rat. Neuroscience 51 (1992) 533-545
123. Lastres-Becker I., Berrendero F., Lucas J.J., Martin-Aparicio E., Yamamoto A., Ramos J.A., and Fernandez-Ruiz J.J. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease. Brain Res. 929 (2002) 236-242
124. Lastres-Becker I., Bizat N., Boyer F., Hantraye P., Brouillet E., and Fernandez-Ruiz J. Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate. Neuroreport 14 (2003) 813-816
125. Lei W., Jiao Y., Del Mar N., and Reiner A. Evidence for differential cortical input to direct pathway versus indirect pathway striatal projection neurons in rats. J. Neurosci. 24 (2004) 8289-8299
126. Levine M.S., Klapstein G.J., Koppel A., Gruen E., Cepeda C., Vargas M.E., Jokel E.S., Carpenter E.M., Zanjani H., Hurst R.S., Efstratiadis A., Zeitlin S., and Chesselet M.-F. Enhanced sensitivity to N-methyl-d-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res. 58 (1999) 515-532
127. Levine M.S., Cepeda C., Hickey M.A., Fleming S.M., and Chesselet M.F. Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trends Neurosci. 27 (2004) 691-697
128. Levine, M.S., Wu, N., Cepeda, C., Leavitt, B.R., Hayden, M.R., 2005. Alterations in corticostriatal synaptic responses in mouse models of Huntington's disease. Soc. Neurosci. Abstr. (Program No. 90.10).
129. Li H., Li S.H., Cheng A.L., Mangiarini L., Bates G.P., and Li X.J. Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Hum. Mol. Genet. 8 (1999) 1227-1236
130. Li H., Li S.H., Johnston H., Shelbourne P.F., and Li X.J. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat. Genet. 25 (2000) 385-389
131. Li H., Wyman T., Yu Z.X., Li S.H., and Li X.J. Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release. Hum. Mol. Genet. 12 (2003) 2021-2030
132. Li J.-Y., Plomann M., and Brundin P. Huntington's disease: a synaptopathy. Trends Mol. Med. 9 (2003) 414-420
133. Li L., Fan M., Icton C.D., Chen N., Leavitt B.R., Hayden M.R., Murphy T.H., and Raymond L.A. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. Neurobiol. Aging 24 (2003) 1113-1121
134. Li L., Murphy T.H., Hayden M.R., and Raymond L.A. Enhanced striatal NR2B containing N-methyl-d-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. J. Neurophysiol. 92 (2004) 2738-2746
135. Li S.H., Gutekunst C.A., Hersch S.M., and Li X.J. Interaction of huntingtin-associated protein with dynactin P150Glued. J. Neurosci. 18 (1998) 1261-1269
136. Li Y.X., Zhang Y., Lester H.A., Schuman E.M., and Davidson N. Enhancement of neurotransmitter release induced by brain-derived neurotrophic factor in cultured hippocampal neurons. J. Neurosci. 18 (1998) 10231-10240
137. Liévens J.C., Woodman B., Mahal A., Spasic-Boscovic O., Samuel D., Kerkerian-Le Goff L., and Bates G.P. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol. Dis. 8 (2001) 807-821
138. Liévens J.C., Woodman B., Mahal A., and Bates G.P. Abnormal phosphorylation of synapsin I predicts a neuronal transmission impairment in the R6/2 Huntington's disease transgenic mice. Mol. Cell. Neurosci. 20 (2002) 638-648
139. Lin C.H., Tallaksen-Greene S., Chien W.M., Cearley J.A., Jackson W.S., Crouse A.B., Ren S., Li X.J., Albin R.L., and Detloff P.J. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet. 10 (2001) 137-144
140. Lione L.A., Carter R.J., Hunt M.J., Bates G.P., Morton A.J., and Dunnett S.B. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J. Neurosci. 19 (1999) 10428-10437
141. Loeb C., Roccatagliata G., Albano C., and Besio G. Bromocriptine and dopaminergic function in Huntington disease. Neurology 29 (1979) 730-734
142. Lovinger D.M., and Choi S. Activation of adenosine A1 receptors initiates short-term synaptic depression in rat striatum. Neurosci. Lett. 199 (1995) 9-12
143. Lovinger D.M., and McCool B.A. Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGLuR2 or 3. J. Neurophysiol. 73 (1995) 1076-1083
144. Lovinger D.M., Tyler E., Fidler S., and Merritt A. Properties of a presynaptic metabotropic glutamate receptor in rat neostriatal slices. J. Neurophysiol. 69 (1993) 1236-1244
145. Lozovaya N.A., Kopanitsa M.V., Boychuk Y.A., and Krishtal O.A. Enhancement of glutamate release uncovers spillover-mediated transmission by N-methyl-d-aspartate receptors in the rat hippocampus. Neuroscience 91 (1999) 1321-1330
146. Luthi-Carter R., Strand A., Peters N.L., Solano S.M., Hollingsworth Z.R., Menon A.S., Frey A.S., Spektor B.S., Penney E.B., Schilling G., Ross C.A., Borchelt D.R., Tapscott S.J., Young A.B., Cha J.H., and Olson J.M. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 9 (2000) 1259-1271
147. MacDonald V., and Halliday G. Pyramidal cell loss in motor cortices in Huntington's disease. Neurobiol. Dis. 10 (2002) 378-386
148. MacGibbon G.A., Hamilton L.C., Crocker S.F., Costain W.J., Murphy K.M., Robertson H.A., and Denovan-Wright E.M. Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice. J. Neurosci. Res. 67 (2002) 372-378
149. Mahon S., Deniau J.M., and Charpier S. Corticostriatal plasticity: life after the depression. Trends Neurosci. 27 (2004) 460-467
150. Malenka R.C., and Kocsis J.D. Presynaptic actions of carbachol and adenosine on corticostriatal synaptic transmission studied in vitro. J. Neurosci. 8 (1988) 3750-3756
151. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., and Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996) 493-506
152. Mary V., Wahl F., and Stutzmann J.M. Effect of riluzole on quinolinate-induced neuronal damage in rats: comparison with blockers of glutamatergic neurotransmission. Neurosci. Lett. 201 (1995) 92-96
153. McCaw E.A., Hu H., Gomez G.T., Hebb A.L., Kelly M.E., and Denovan-Wright E.M. Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. Eur. J. Biochem. 271 (2004) 4909-4920
154. McGeer E.G., McGeer P.L., and Singh K. Kainate-induced degeneration of neostriatal neurons: dependency upon corticostriatal tract. Brain Res. 139 (1978) 381-383
155. Menalled L.B., and Chesselet M.F. Mouse models of Huntington's disease. Trends Pharmacol. Sci. 23 (2002) 32-39
156. Menalled L., Zanjani H., MacKenzie L., Koppel A., Carpenter E., Zeitlin S., and Chesselet M.-F. Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease. Exp. Neurol. 162 (2000) 328-342
157. Menalled L.B., Sison J.D., Wu Y., Olivieri M., Li X.J., Li H., Zeitlin S., and Chesselet M.F. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J. Neurosci. 22 (2002) 8266-8276
158. Menalled L.B., Sison J.D., Dragatsis I., Zeitlin S., and Chesselet M.F. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J. Comp. Neurol. 465 (2003) 11-26
159. Milnerwood A.J., Cummings D.M., Dallerac G.M., Brown J.Y., Vatsavayai S.C., Hirst M.C., Rezaie P., and Murphy K.P. Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease. Hum. Mol. Genet. 15 (2006) 1690-1703
160. Mitchell I.J., Cooper A.J., and Griffiths M.R. The selective vulnerability of striatopallidal neurons. Prog. Neurobiol. 59 (1999) 691-719
161. Mizuta I., Ohta M., Ohta K., Nishimura M., Mizuta E., and Kuno S. Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosci. Lett. 310 (2001) 117-120
162. Morton A.J., and Leavens W. Mice transgenic for the human Huntington's disease mutation have reduced sensitivity to kainic acid toxicity. Brain Res. Bull. 52 (2000) 51-59
163. Morton A.J., Lagan M.A., Skepper J.N., and Dunnett S.B. Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation. J. Neurocytol. 29 (2000) 679-702
164. Morton A.J., and Edwardson J.M. Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease. J. Neurochem. 76 (2001) 166-172
165. Morton A.J., Faull R.L., and Edwardson J.M. Abnormalities in the synaptic vesicle fusion machinery in Huntington's disease. Brain Res. Bull. 56 (2001) 111-117
166. Murphy K.P., Carter R.J., Lione L.A., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., and Morton A.J. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J. Neurosci. 20 (2000) 5115-5123
167. Naver B., Stub C., Moller M., Fenger K., Hansen A.K., Hasholt L., and Sorensen S.A. Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse. Neuroscience 122 (2003) 1049-1057
168. NicNiocaill B., Haraldsson B., Hansson O., O'Connor W.T., and Brundin P. Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice. Eur. J. Neurosci. 13 (2001) 206-210
169. Nisenbaum E.S., Berger T.W., and Grace A.A. Presynaptic modulation by GABAB receptors of glutamatergic excitation and GABAergic inhibition of neostriatal neurons. J. Neurophysiol. 67 (1992) 477-481
170. Nisenbaum E.S., and Wilson C.J. Potassium currents responsible for inward and outward rectification in rat neostriatal spiny projection neurons. J. Neurosci. 15 (1995) 4449-4463
171. Orlando L.R., Standaert D.G., Penney Jr. J.B., and Young A.B. Metabotropic receptors in excitotoxicity: (S)-4-carboxy-3-hydroxyphenylglycine ((S)-4C3HPG) protects against rat striatal quinolinic acid lesions. Neurosci. Lett. 202 (1995) 109-112
172. Orlando L.R., Alsdorf S.A., Penney Jr. J.B., and Young A.B. The role of group I and group II metabotropic glutamate receptors in modulation of striatal NMDA and quinolinic acid toxicity. Exp. Neurol. 167 (2001) 196-204
173. Pang T.Y., Stam N.C., Nithianantharajah J., Howard M.L., and Hannan A.J. Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in huntington's disease transgenic mice. Neuroscience 141 (2006) 569-584
174. Perez-Navarro E., Canudas A.M., Akerund P., Alberch J., and Arenas E. Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease. J. Neurochem. 75 (2000) 2190-2199
175. Perutz M.F. Glutamine repeats and neurodegenerative diseases: molecular aspects. Trends Biochem. Sci. 24 (1999) 58-63
176. Petersén A., Hansson O., Puschban Z., Sapp E., Romero N., Castilho R.F., Sulzer D., Rice M., DiFiglia M., Przedborski S., and Brundin P. Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine. Eur. J. Neurosci. 14 (2001) 1425-1435
177. Petersén A., Chase K., Puschban Z., DiFiglia M., Brundin P., and Aronin N. Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease. Exp. Neurol. 175 (2002) 297-300
178. Petersén A., Gil J., Maat-Schieman M.L., Bjorkqvist M., Tanila H., Araujo I.M., Smith R., Popovic N., Wierup N., Norlen P., Li J.Y., Roos R.A., Sundler F., Mulder H., and Brundin P. Orexin loss in Huntington's disease. Hum. Mol. Genet. 14 (2005) 39-47
179. Picconi B., Passino E., Sgobio C., Bonsi P., Barone I., Ghiglieri V., Pisani A., Bernardi G., Ammassari-Teule M., and Calabresi P. Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons. Neurobiol. Dis. 22 (2006) 143-152
180. Plotkin J.L., Wu N., Chesselet M.F., and Levine M.S. Functional and molecular development of striatal fast-spiking GABAergic interneurons and their cortical inputs. Eur. J. Neurosci. 22 (2005) 1097-1108
181. 2+ dynamics in the striatum of the R6/2 mouse model of Huntington's disease. Soc. Neurosci. Abstr. (Program No. 472.3).
182. Popoli P., Pintor A., Domenici M.R., Frank C., Tebano M.T., Pezzola A., Scarchilli L., Quarta D., Reggio R., Malchiodi-Albedi F., Falchi M., and Massotti M. Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J. Neurosci. 22 (2002) 1967-1975
183. Quinn N., and Marsden C.D. A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. J. Neurol. Neurosurg. Psychiatry 47 (1984) 844-847
184. Rasmussen A., Macias R., Yescas P., Ochoa A., Davila G., and Alonso E. Huntington disease in children: genotype-phenotype correlation. Neuropediatrics 31 (2000) 190-194
185. Rebec G.V., Conroy S.K., and Barton S.J. Hyperactive striatal neurons in symptomatic Huntington R6/2 mice: variations with behavioral state and repeated ascorbate treatment. Neuroscience 137 (2006) 327-336
186. Reiner A. Can lesions of GPe correct HD deficits?. Exp. Neurol. 186 (2004) 1-5
187. Reiner A., Albin R.L., Anderson K.D., D'Amato C.J., Penney J.B., and Young A.B. Differential loss of striatal projection neurons in Huntington disease. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 5733-5737
188. Richfield E.K., Maguire-Zeiss K.A., Vonkeman H.E., and Voorn P. Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients. Ann. Neurol. 38 (1995) 852-861
189. Rosas H.D., Koroshetz W.J., Jenkins B.G., Chen Y.I., Hayden D.L., Beal M.F., and Cudkowicz M.E. Riluzole therapy in Huntington's disease (HD). Mov. Disord. 14 (1999) 326-330
190. Rosas H.D., Liu A.K., Hersch S., Glessner M., Ferrante R.J., Salat D.H., van der Kouwe A., Jenkins B.G., Dale A.M., and Fischl B. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 58 (2002) 695-701
191. Rubinsztein D.C. Lessons from animal models of Huntington's disease. Trends Genet. 18 (2002) 202-209
192. Sapp E., Ge P., Aizawa H., Bird E., Penney J., Young A.B., Vonsattel J.P., and DiFiglia M. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis. Neuroscience 64 (1995) 397-404
193. Sapp E., Penney J., Young A.B., Aronin N., Vonsattel J.P., and DiFiglia M. Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. J. Neuropathol. Exp. Neurol. 58 (1999) 165-173
194. Sattler R., Xiong Z., Lu W.Y., MacDonald J.F., and Tymianski M. Distinct roles of synaptic and extrasynaptic NMDA receptors in excitotoxicity. J. Neurosci. 20 (2000) 22-33
195. Schiefer J., Alberty A., Dose T., Oliva S., Noth J., and Kosinski C.M. Huntington's disease transgenic mice are resistant to global cerebral ischemia. Neurosci. Lett. 334 (2002) 99-102
196. Schiefer J., Landwehrmeyer G.B., Luesse H.G., Sprunken A., Puls C., Milkereit A., Milkereit E., and Kosinski C.M. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Mov. Disord. 17 (2002) 748-757
197. Schiefer J., Sprunken A., Puls C., Luesse H.G., Milkereit A., Milkereit E., Johann V., and Kosinski C.M. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease. Brain Res. 1019 (2004) 246-254
198. Schrott L.M. Effect of training and environment on brain morphology and behavior. Acta Paediatr. Suppl. 422 (1997) 45-47
199. Segal M. Dendritic spines for neuroprotection: a hypothesis. Trends Neurosci. 18 (1995) 468-471
200. Shehadeh J., Fernandes H.B., Zeron-Mullins M.M., Graham R.K., Leavitt B.R., Hayden M.R., and Raymond L.A. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiol. Dis. 21 (2006) 392-403
201. Shelbourne P.F., Killeen N., Hevner R.F., Johnston H.M., Tecott L., Lewandoski M., Ennis M., Ramirez L., Li Z., Iannicola C., Littman D.R., and Myers R.M. A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum. Mol. Genet. 8 (1999) 763-774
202. Shoulson I., Goldblatt D., Charlton M., and Joynt R.J. Huntington's disease: treatment with muscimol, a GABA-mimetic drug. Ann. Neurol. 4 (1978) 279-284
203. Shoulson I., Odoroff C., Oakes D., Behr J., Goldblatt D., Caine E., Kennedy J., Miller C., Bamford K., Rubin A., Plumb S., and Kurlan R. A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann. Neurol. 25 (1989) 252-259
204. Sieradzan K.A., and Mann D.M. The selective vulnerability of nerve cells in Huntington's disease. Neuropathol. Appl. Neurobiol. 27 (2001) 1-21
205. Slow E.J., van Raamsdonk J., Rogers D., Coleman S.H., Graham R.K., Deng Y., Oh R., Bissada N., Hossain S.M., Yang Y.Z., Li X.J., Simpson E.M., Gutekunst C.A., Leavitt B.R., and Hayden M.R. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 12 (2003) 1555-1567
206. Slow E.J., Graham R.K., and Hayden M.R. To be or not to be toxic: aggregations in Huntington and Alzheimer disease. Trends Genet. (2006) June 25 [Epub ahead of print]
207. Smith A.D., and Bolam J.P. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci. 13 (1990) 259-265
208. Smith A.D., and Zigmond M.J. Can the brain be protected through exercise? Lessons from an animal model of parkinsonism. Exp. Neurol. 184 (2003) 31-39
209. Smith Y., Bevan M.D., Shink E., and Bolam J.P. Microcircuitry of the direct and indirect pathways of the basal ganglia. Neurosci. 86 (1998) 353-387
210. Smith R., Musleh W., Akopian G., Buckwalter G., and Walsh J.P. Regional differences in the expression of corticostriatal synaptic plasticity. Neuroscience 106 (2001) 95-101
211. Smith R., Brundin P., and Li J.Y. Synaptic dysfunction in Huntington's disease: a new perspective. Cell Mol. Life Sci. 62 (2005) 1901-1912
212. Smith R., Petersen A., Bates G.P., Brundin P., and Li J.Y. Depletion of rabphilin 3A in a transgenic mouse model (R6/1) of Huntington's disease, a possible culprit in synaptic dysfunction. Neurobiol. Dis. 20 (2005) 673-684
213. Sotrel A., Paskevich P.A., Kiely D.K., Bird E.D., Williams R.S., and Myers R.H. Morphometric analysis of the prefrontal cortex in Huntington's disease. Neurology 41 (1991) 1117-1123
214. Spencer J.P., and Murphy K.P. Bi-directional changes in synaptic plasticity induced at corticostriatal synapses in vitro. Exp. Brain Res. 135 (2000) 497-503
215. Spires T.L., Grote H.E., Garry S., Cordery P.M., Van Dellen A., Blakemore C., and Hannan A.J. Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice. Eur. J. Neurosci. 19 (2004) 2799-2807
216. Standaert D.G., Friberg I.K., Landwehrmeyer G.B., Young A.B., and Penney Jr. J.B. Expression of NMDA glutamate receptor subunit mRNAs in neurochemically identified projection and interneurons in the striatum of the rat. Brain Res. Mol. Brain Res. 64 (1999) 11-23
217. Starling A.J., André V.M., Cepeda C., de Lima M., Chandler S.H., and Levine M.S. Alterations in N-methyl-d-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease. J. Neurosci. Res. 82 (2005) 377-386
218. Strong T.V., Tagle D.A., Valdes J.M., Elmer L.W., Boehm K., Swaroop M., Kaatz K.W., Collins F.S., and Albin R.L. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nat. Genet. 5 (1993) 259-265
219. Sun Y., Savanenin A., Reddy P.H., and Liu Y.F. Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-d-aspartate receptors via post-synaptic density 95. J. Biol. Chem. 276 (2001) 24713-24718
220. Surmeier D.J., Song W.J., and Yan Z. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J. Neurosci. 16 (1996) 6579-6591
221. Swayne L.A., Chen L., Hameed S., Barr W., Charlesworth E., Colicos M.A., Zamponi G.W., and Braun J.E. Crosstalk between huntingtin and syntaxin 1A regulates N-type calcium channels. Mol. Cell. Neurosci. 30 (2005) 339-351
222. Tabrizi S.J., Workman J., Hart P.E., Mangiarini L., Mahal A., Bates G., Cooper J.M., and Schapira A.H. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann. Neurol. 47 (2000) 80-86
223. A synaptic responses by brain-derived neurotrophic factor (BDNF) in rat hippocampus. J. Neurosci. 17 (1997) 2959-2966
224. Tarditi A., Camurri A., Varani K., Borea P.A., Woodman B., Bates G., Cattaneo E., and Abbracchio M.P. Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease. Neurobiol. Dis. 23 (2006) 44-53
225. Tobin A.J., and Signer E.R. Huntington's disease: the challenge for cell biologists. Trends Cell Biol. 10 (2000) 531-536
226. Tovar K.R., and Westbrook G.L. The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J. Neurosci. 19 (1999) 4180-4188
227. Turmaine M., Raza A., Mahal A., Mangiarini L., Bates G.P., and Davies S.W. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 8093-8097
228. Uhl G.R., Navia B., and Douglas J. Differential expression of preproenkephalin and preprodynorphin mRNAs in striatal neurons: high levels of preproenkephalin expression depend on cerebral cortical afferents. J. Neurosci. 8 (1988) 4755-4764
229. Usdin M.T., Shelbourne P.F., Myers R.M., and Madison D.V. Impaired synaptic plasticity in mice carrying the Huntington's disease mutation. Hum. Mol. Genet. 8 (1999) 839-846
230. Uzgil B., Cepeda C., Wu N., Buchwald N.A., and Levine M.S. Increased cortical excitability in the R6/2 mouse model of Huntington's disease. Soc. Neurosci. Abst. 30 (2004) 564.2
231. van Dellen A., Blakemore C., Deacon R., York D., and Hannan A.J. Delaying the onset of Huntington's in mice. Nature 404 (2000) 721-722
232. Vonsattel J.P., and DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 57 (1998) 369-384
233. Vonsattel J.P., Meyers R.H., Stevens T.J., Ferrante R.J., Bird E.D., and Richardson Jr. E.P. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44 (1985) 559-577
234. Waddington J.L., and Cross A.J. Therapeutic failure of GABA agonist treatment in Huntington's disease. Neurology 34 (1984) 702
235. Wheeler V.C., White J.K., Gutekunst C.A., Vrbanac V., Weaver M., Li X.J., Li S.H., Yi H., Vonsattel J.P., Gusella J.F., Hersch S., Auerbach W., Joyner A.L., and MacDonald M.E. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum. Mol. Genet. 9 (2000) 503-513
236. White J.K., Auerbach W., Duyao M.P., Vonsattel J.P., Gusella J.F., Joyner A.L., and MacDonald M.E. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat. Genet. 17 (1997) 404-410
237. Wilson C.J., and Kawaguchi Y. The origins of two-state spontaneous membrane potential fluctuations of neostriatal spiny neurons. J. Neurosci. 16 (1996) 2397-2410
238. Wong P.T., McGeer P.L., Rossor M., and McGeer E.G. Ornithine aminotransferase in Huntington's disease. Brain Res. 231 (1982) 466-471
239. Wood J.D., MacMillan J.C., Harper P.S., Lowenstein P.R., and Jones A.L. Partial characterisation of murine huntingtin and apparent variations in the subcellular localisation of huntingtin in human, mouse and rat brain. Hum. Mol. Genet. 5 (1996) 481-487
240. Wu, N., Starling, A.J., Cepeda, C., Levine, M.S., 2004. Striatal synaptically-evoked currents in a mouse model of Huntington's disease. Soc. Neurosci. Abstr. (Program No. 564.10).
241. Wüllner U., Young A.B., Penny J.B., and Beal M.F. 3-Nitropropionic acid toxicity in the striatum. J. Neurochem. 63 (1994) 1772-1781
242. Yamamoto A., Lucas J.J., and Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101 (2000) 57-66
243. Yin H.H., and Lovinger D.M. Frequency-specific and D2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signaling. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 8251-8256
244. Young A.B. Huntingtin in health and disease. J. Clin. Invest. 111 (2003) 299-302
245. Zeron M.M., Hansson O., Chen N., Wellington C.L., Leavitt B.R., Brundin P., Hayden M.R., and Raymond L.A. Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33 (2002) 849-860
246. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., MacDonald M.E., Friedlander R.M., Silani V., Hayden M.R., Timmusk T., Sipione S., and Cattaneo E. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293 (2001) 493-498
247. Zuccato C., Liber D., Ramos C., Tarditi A., Rigamonti D., Tartari M., Valenza M., and Cattaneo E. Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol. Res. 52 (2005) 133-139
248. Zuchora B., Turski W.A., Wielosz M., and Urbanska E.M. Protective effect of adenosine receptor agonists in a new model of epilepsy-seizures evoked by mitochondrial toxin, 3-nitropropionic acid, in mice. Neurosci. Lett. 305 (2001) 91-94